SecBot SecBot
8-K ·Filed Apr 23, 2026

LUCD

Lucid Diagnostics Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001493152-26-018725
8-K material event: Items 1.01
Actionable Insight • Neutral

Monitor the company's cash position and burn rate in the next quarterly filing to assess how effectively the new capital is being deployed. Watch for any changes in guidance that might reflect the impact of this capital raise.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
LUCD ▼ -9.65% at T+60d
NEUTRAL call -9.65% · α vs SPY -14.73% · entry $1.07 → $0.9667
Entry = T+0 close
Apr 23, 2026
via day close
T+1d
-0.93%
call -0.93% · α -1.10%
$1.06
settled 6mo ago
T+5d
0.00%
call 0.00% · α -0.91%
$1.07
settled 6mo ago
T+20d
-6.54%
call -6.54% · α -10.57%
$1.00
settled 5mo ago
T+60d
-9.65%
call -9.65% · α -14.73%
$0.9667
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Lucid Diagnostics is conducting an underwritten public offering of 18 million shares of common stock at a public offering price of $1.00 per share, with gross proceeds of $18 million before expenses. The offering is being led by Canaccord Genuity and BTIG as joint bookrunners, and the proceeds will be used for working capital and general corporate purposes.

Key Financial Metrics

Deal Value
$18.0M

Key Facts

  • Lucid Diagnostics is offering 18,000,000 shares of common stock
  • Public offering price is $1.00 per share
  • Gross proceeds will be approximately $18 million before deducting underwriting discounts and commissions
  • Offering is being conducted through an underwriting agreement with Canaccord Genuity LLC and BTIG, LLC as representatives
  • Proceeds will be used for working capital and general corporate purposes
  • The offering is being made pursuant to a shelf registration statement on Form S-3 that became effective on March 26, 2026

Financial Impact

Approximately $18 million in gross proceeds from the sale of 18 million shares at $1.00 per share

cashdilutionequity

Risk Factors

  • Dilution to existing shareholders from the issuance of new shares
  • Potential downward pressure on stock price due to increased share count
  • Risk that the company may not effectively deploy the capital for growth

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-018725
Exhibit: ex99-1.htm0001493152-26-018725
Exhibit: ex5-1.htm0001493152-26-018725
Document: form8-k.htm0001493152-26-018725
Document: 0001493152-26-018725-index-headers.html0001493152-26-018725
Document: 0001493152-26-018725-index.html0001493152-26-018725
Document: 0001493152-26-018725.txt0001493152-26-018725
7 reports for LUCD
Performance horizon
50% Hit rate @ T+1 2 of 4 directional calls Went positive at some point 2 of 4 best @ T+1▲ +6.63%Oct 16, 2026
Filters
Rows
Reports for LUCD — sortable, filterable
TypeNow
Oct 22, 2026
4d ago
8-K
BEARISH ★ 6/10
$0.4110 $0.5007▼ −21.82%▼ −21.11%$0.4720 (−14.84%)
Oct 16, 2026
10d ago
8-K
BEARISH ★ 7/10
$0.3770 $0.3520▲ +6.63%▲ +6.97%$0.4720 (−25.20%)
Sep 22, 2026
5w ago
8-K
BULLISH ★ 5/10
$0.8930 $0.8390▼ −6.05%▼ −5.33%$0.4720 (−47.14%)
Aug 13, 2026
10w ago
8-K
MIXED ★ 5/10
$0.9649 $0.9677▲ +0.29%▲ +0.49%$0.4720 (−51.08%)
May 14, 2026
23w ago
8-K
BEARISH ★ 5/10
$1.02 $0.9910▲ +2.84%▲ +1.62%$0.4720 (+53.73%)
Apr 24, 2026
26w ago
8-K
NEUTRAL ★ 5/10
$1.06 $1.04▼ −1.89%▼ −1.40%$0.4720 (−55.47%)
Apr 23, 2026
26w ago
8-K
NEUTRAL ★ 5/10
$1.07 $1.06▼ −0.93%▼ −1.10%$0.4720 (−55.89%)
Showing 7 of 7

US Market Status

Market Open — Closes in 3h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026